Skip to content

Peak Flow Monitoring in Older Adults With Asthma

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00149474
Enrollment
Unknown
Registered
2005-09-08
Start date
1994-08-31
Completion date
1999-07-31
Last updated
2016-02-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma

Brief summary

Evaluate the incremental effectiveness of peak flow monitoring ove symptom monitoring as a management tool to enhance asthma control in adults \>= 50 years with moderate-severe asthma.

Detailed description

BACKGROUND: We propose a five-year Demonstration and Education project to assess the incremental value of peak flow monitoring (PFM) over symptom monitoring (SM) as a management tool for asthma control in adults greater than or equal to 50 years with moderate-severe asthma. We will develop three parallel asthma education programs for older adults using as our base an existing asthma education program (AIR/Kaiser Adult Education Program) of demonstrated efficacy for adults ,50 years of age. DESIGN NARRATIVE: Primary outcome Frequency and cost of health care utilization for asthma, and asthma-specific quality of life Key secondary outcomes Prebronchodilator FEV1; diurnal variability in PEF The study completion date listed in this record was obtained from the End Date entered in the Protocol Registration and Results System (PRS) record.

Interventions

BEHAVIORALPeak Flow Monitoring

Sponsors

National Heart, Lung, and Blood Institute (NHLBI)
Lead SponsorNIH

Study design

Allocation
RANDOMIZED

Eligibility

Sex/Gender
ALL
Age
50 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

Inclusions: Doctor-diagnosed asthma; \>=50 years; using asthma medications; \>12% increase in FEV1 after two puffs of inhaled beta-agonist; willing to participate in asthma meducation program and two-year follow up; likely to stay in Portland area; KPNW member for two years. Exclusions: Unable to read, speak or understand English; no telephone; failure to keep two pre-randomization appointments; inability to reproducible FEV 1 maneuver; participation in pilot phase of study; concurrent participation in any other medical research study.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026